Granulation tissue formation promotion

Granulation tissue formation is the critical phase of wound healing in which a highly vascularized, cellular tissue temporarily replaces damaged or lost tissue at an injury site. Granulation tissue is composed of proliferating fibroblasts, myofibroblasts, inflammatory cells (such as neutrophils, macrophages, and lymphocytes), and a newly formed extracellular matrix rich in type III collagen, transitioning to type I collagen as healing progresses. This tissue provides a scaffold for re-epithelialization, angiogenesis (formation of new blood vessels), and eventual maturation into scar tissue. Aberrations in granulation tissue formation can result in non-healing wounds (with insufficient granulation) or excessive scar (fibrotic granulation and contractures). Granulation tissue formation is not a single protein, receptor, or drug target; it is a complex process regulated by cytokines, growth factors (e.g., TGF-β, PDGF, VEGF), and cell types such as fibroblasts, endothelial cells, and macrophages. Drugs and interventions may promote or modulate granulation tissue by targeting mediators or cells involved in its formation, but "granulation tissue formation" by itself is not directly druggable. Examples of drugs and therapies that promote granulation tissue indirectly include: topical growth factors, negative pressure wound therapy (NPWT), and platelet-derived preparations. Biomarkers and safety concerns in this context are linked to the underlying mediating molecules (e.g., TGF-β for fibrosis risk, infection markers for inadequate granulation), not the process itself.

Other names

granulation tissue inductionwound granulation promotiontissue granulation enhancement